Coulter Funded Projects

UVA-Coulter builds networks of relationships around our researchers, connecting them with veteran entrepreneurs, investors and experts in such fields as clinical trials, regulation, and patents and licensing. Because every new technology has its own requirements and follows its own path to the marketplace, we approach each project differently. The exchange of ideas, insight and information is the engine that moves innovative technologies from university laboratories to the marketplace. We now have twelve years’ experience taking biomedical innovations born in the academic environment and translating them into practical use.

  • Coulter Team led by Don Griffin
  • Coulter Project in the NICU


  • Cerillo World's Smallest Multiwell Plate Reader

Projects Funded for 2020-2021

  • Injectable fibrous hydrogels for treating pelvic organ prolapse

    Steven Caliari, PhD (BME and CHEM Eng) and Monique Vaughan, MD (Obstetrics and Gynecology)

    There is an urgent clinical need for innovation in the field of prolapse surgery and tissue engineering approaches to augment prolapse repair. Pelvic floor disorders (PFDs) are common and can have a significant impact on a woman’s quality of life, sense of well-being, body image, and sexuality. Pelvic organ prolapse (POP) in particular affects millions of women worldwide; approximately 11% of women in the United States will undergo surgery for prolapse or urinary incontinence.  The central objectives of this proposal are to: 1) optimize the formulation of a material that can be delivered in a minimally invasive manner during prolapse surgery, and 2) assess the biocompatibility and therapeutic efficacy of our technology. 

  • Vaccines for effective mucosal immunity against SARS-CoV-2

    Peter Kasson, M.D., PhD (BME and Molecular Physiology) and Willam Petri M.D., PhD (Pathology)

    The COVID-19 pandemic has caused over 3 million confirmed infections already, and most of the world’s population is expected to be at risk of infection over the coming years. Initial vaccines are entering clinical trials, and recovered individuals are being monitored for reinfection, but it remains unclear whether either first generation vaccines or natural infection can induce lasting, sterilizing immunity to prevent reinfection and transmission. This project aims to create a vaccine candidate that is mucosally targeted and elicits broad, long-lasting protection.

  • Conformation-specific antibody as therapy for Idiopathic Pulmonary Fibrosis

    Tom Barker, Ph.D. (BME) and James Hagood, MD (Pulmonology)

    Idiopathic pulmonary fibrosis (IPF) is the most prevalent interstitial lung disease with an incidence of 20 to 60 cases per hundred thousand people in the US. The disease etiology remains mostly unknown and, apart from lung transplants which often fail within a few years, few treatment options exist. In this Coulter project, we will discover the highest tolerated dose of our engineered antibody, H5 (1), examine its potential to stop disease progression in murine models of lung fibrosis (2), and collect further Pk/Pd data (3).

  • Design and Implementation of Critical Quality Attributes (CQA’s) for Biomanufacturing of Tissue Engineered Medical Products (TEMPs) in a “Closed-Loop” Bioreactor System

    George Christ, PhD (BME) and Bobby Chhabra, MD (Orthopaedic Surgery)

    The technology platform leveraged herein is a novel and innovative (r)evolution of a biomanufacturing process originally developed for the treatment of Volumetric Muscle Loss (VML) injuries to wounded warriors and civilians.  This new biofabrication process leverages significant resources and lessons learned from that process, and thus, already provides a clinically-relevant test bed for further development — although numerous other applications of this innovative technology platform are possible (vessel, tendon, ligament, etc.). The goal of this proposal is to include nondestructive Critical Quality Attributes (CQAs), as part of our proprietary advanced biomanufacturing system for Tissue Engineered Medical Products (TEMPs).

  • Development of a DEep Spiral Image REconstruction (DESIRE) framework for On-line Rapid Spiral CMR Perfusion Imaging

    Michael Salerno M.D., Ph.D.(Cardiovascular Medicine/BME) and Dan Weller M.D., Ph.D. (BME and Radiology)

    The goal of this Coulter project is to develop, implement, and evaluate a DEep Spiral Image REconstruction (DESIRE) framework for rapid spiral perfusion image reconstruction. This approach will then be extended to other spiral techniques developed in our lab including cine, T1 mapping and late gadolinium enhancement. Specifically we are interested in developing DL techniques based on CNN architectures that enforce non-Cartesian multi-coil data fidelity.

  • Super Resolution / Molecular Imaging for Improved Prostate Cancer Diagnostic Performance

    John Hossack, PhD (BME) and Sumit Isharwal, M.D. (Urology)

    The limitations of the PSA blood test and digital rectal examination to diagnose prostate cancer are well established. Current clinical practice primarily relies on a systematic 12 core biopsy and, in some cases, multi-parametric MRI (mpMRI). We see to non-invasively characterize prostate lesions with regard to microvascular features and tumor biomarkers using a low cost, radiation free, mobile and readily available technology – specifically newly developed ultrasound-based technology. We are developing an ultrasound molecular imaging of prostate-specific membrane antigen (PSMA) combined with super-resolution ultrasound localization microscopy.

  • Reduced genome surface expressed immunogen recombinant minicell bacterial vaccines and the challenge of Covid-19

    Mark Kester, PhD (Pharmacology & BME) and Steven Zeichner, M.D. (Pediatrics)

    The project centers on advanced analysis of Big Data captured from continuous cardiorespiratory monitoring, here in the special case of premature infants. The UVa Center for Advanced Medical Analytics has a unique opportunity to advance the field of predictive analytics monitoring through a new approach of highly comparative time series analysis, using the largest database of clinical and cardiorespiratory monitoring data extant, generated by 2 ongoing NIH multicenter grants. This will result in new families of algorithms for early detection of subacute potentially catastrophic illnesses.